P5
LIVE

Serial Number

79418922

Owner

Tubulis GmbH

Attorney

Ryan D. Artis

Filing Date

Feb 6, 2025

Add to watchlist:

No watchlists yet
View on USPTO

P5 Trademark

Serial Number: 79418922 • Registration: 8226653

P5 is a trademark filed by Tubulis GmbH on February 6, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Tubulis GmbH (4 trademarks)

Am Klopferspitz 19a
Planegg D-82152 , DE

Entity Type: 99

Trademark Details

Filing Date

February 6, 2025

Registration Date

April 28, 2026

Published for Opposition

March 10, 2026

Goods & Services

Chemical, biochemical, biological, and biotechnological preparations, in particular, antibodies, fragments of antibodies and antibody-drug conjugates for industrial and scientific use; antibodies, fragments of antibodies and antibody-drug conjugates for the development or manufacture of therapeutic reagents for industrial and scientific use; biological preparations, in particular, antibodies, fragments of antibodies and antibody-drug conjugates for laboratories, diagnostics and analytics for scientific or research use; chemical, biochemical, biological, and biotechnological preparations for industrial and scientific use.

Scientific and technological services, namely scientific research, analysis, testing and design in the fields of biology, chemistry and medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations, biomarker reagents and diagnostic apparatus​​​​​​​

Pharmaceutical and veterinary preparations and substances for the treatment of cancer, inflammatory diseases, autoimmune diseases, infective diseases, cardiovascular diseases, liver metabolic disorders and other conditions which can be treated or ameliorated by antibodies binding to, or activation or blocking of, a target antigen; therapeutic pharmaceuticals, namely antibody-drug conjugates for the treatment of cancer and autoimmune diseases; pharmaceutical and veterinary preparations for the treatment of cancer, inflammatory diseases, autoimmune diseases, infective diseases, cardiovascular diseases and liver metabolic disorders comprising small molecules; small molecule compounds being pharmaceuticals for the treatment of cancer

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2026 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 16, 2026 NREP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 13, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 13, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 13, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 13, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 13, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 4, 2026 TROA
REFUSAL PROCESSED BY IB
Sep 5, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 21, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 20, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 17, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jul 16, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 16, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 16, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 16, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 13, 2025 REPR